GO
Loading...

Pharmaceuticals

More

  • Amgen's D-mab Delights Monday, 28 Jul 2008 | 10:38 AM ET
    AMGEN

    Amgen surprised the market late on a summer Friday by announcing positive test results from the big, crucial study of its experimental osteoporosis drug. The stock shot up after hours and continues to rally this morning.

  • Amgen Shares Leap on Osteoporosis Trial Results Friday, 25 Jul 2008 | 5:27 PM ET

    Amgen shares leaped in late trading Friday after the company said a pivotal trial of its experimental osteoporosis drug denosumab met its goal of significantly reducing the risk of bone fracture in post-menopausal women.

  • The State of Statins & Stents Friday, 25 Jul 2008 | 11:14 AM ET
    Heart Stent

    Leerink Swann, which specializes in healthcare equities research, is out with a couple of noteworthy surveys--one on the collateral damage to Merck and Schering-Plough's Vytorin this week and the other on drug-coated stents from Abbott Labs, Boston Scientific, Johnson & Johnson and Medtronic.

  • Lilly, Pfizer & The Economies of ED Thursday, 24 Jul 2008 | 11:25 AM ET

    So, yesterday I posited a theory that the weak American economy might be hurting sales growth of erectile dysfunction drugs. I wondered whether men might be cutting their pills in half and/or not filling their expensive prescriptions if they're having to tighten their belts.

  • Lilly Profit Rises, But Company Cuts 2008 Forecast Thursday, 24 Jul 2008 | 7:17 AM ET

    Eli Lilly said on Thursday that second-quarter earnings rose on higher sales of its prescription drugs and sharply lower taxes, but the company cut its 2008 profit forecast due to special charges.

  • Is Pfizer's Viagra "Sagging" With The Economy? Wednesday, 23 Jul 2008 | 12:18 PM ET

    On the Pfizer earnings conference call this morning Chairman and CEO Jeff Kindler kicked things off by calling this a "time of great uncertainty in the world economy and capital markets and significant challenges in our industry."

  • Pfizer Profit Doubles on Drug Sales, Lower Costs Wednesday, 23 Jul 2008 | 8:55 AM ET

    Pfizer Wednesday said quarterly earnings more than doubled on higher sales of its prescription drugs and lower expenses, but its Chantix quit-smoking drug lost more than a third of its U.S. sales amid safety concerns.

  • Glaxo Earnings Rise 13%, Cautious on Outlook Wednesday, 23 Jul 2008 | 8:19 AM ET

    GlaxoSmithKline's new chief executive set out plans to make the world's second largest drug maker a broader business with lower costs, but kept a cautious view on short-term prospects that knocked its shares.   

  • Merck KGaA Profit Rises, Slightly Misses Expectations Wednesday, 23 Jul 2008 | 1:53 AM ET

    German drugs and chemicals company Merck KGaA reported a 15 percent rise in second-quarter operating profit on Wednesday thanks to rising sales of liquid crystals and multiple-sclerosis and cancer drugs.

  • Merck And "Sex and the City" Strategy: Did It Work? Tuesday, 22 Jul 2008 | 2:38 PM ET
    Sex and The the City

    Recently I blogged about Merck advertising its cervical cancer vaccine Gardasil to a captive audience during trailers for the "Sex and the City" movie.

  • Yesterday while covering the press conference about the new study on Merck and Schering-Plough's Vytorin I quoted the lead researcher, Dr. Terje Pedersen of Ulleval University Hospital in Oslo, Norway, who said--and this is a direct quote: "However, we had a disturbing finding when we looked at safety."

  • Boston Scientific quarterly earnings fell 15 percent on declining sales of its drug-eluting stents and charges for acquisitions, divestitures and restructuring.

  • Schering-Plough Profit Falls but Tops Forecasts Monday, 21 Jul 2008 | 5:09 PM ET

    Schering-Plough, whose shares fell earlier after its Vytorin cholesterol fighter failed another study, said its earnings fell 23 percent but beat forecasts.

  • Merck Limits Guidance; Posts In-Line Results Monday, 21 Jul 2008 | 5:03 PM ET

    Merck  on Monday said it was not providing long-time financial forecasts as it assesses the impact of another failed study result for its Vytorin cholesterol fighter, which it produces with Schering Plough.

  • Vytorin, a cholesterol drug marketed by drugmakers Merck and Schering-Plough, failed to meet the main goals in a new study, released Monday.

  • Big Merger Deals Signaling Even Bigger Ones Ahead Monday, 21 Jul 2008 | 2:36 PM ET
    Deal, Handshake

    The recent spate of  takeovers, particularly in pharmaceuticals, represents the first step in what analysts expect to be a busier second half of the year for mergers and acquisitions.

  • The buyout offer from Swiss drug giant Roche has shares of DNA trading at their highest level in about two-and-a-half years and according to CNBC stock-stat maven, Robert Hum, if they close up at least 8.88% it'll be their biggest one-day percentage gain since April 15, 2005.

  • What's Genentech Really Worth? Monday, 21 Jul 2008 | 12:12 PM ET
    Genetech

    You have to wonder at markets and analysts for that matter. They are fickle creatures.

  • Big Pharma Is Scrambling To Buy More Biotech Firms Monday, 21 Jul 2008 | 11:11 AM ET

    Roche Holdings' $43.7 billion bid to buy the rest of Genentech highlights drugmakers' growing reliance on biotech products.

  • Merck, Schering Delay Earnings For Vytorin Update Monday, 21 Jul 2008 | 10:10 AM ET

    Merck and Schering-Plough delayed the release of their quarterly  financial results so investors could first learn the outcome of a new study of their Vytorin cholesterol fighter, and both drug makers' shares fell on jitters about the impending trial data.